Spaner David E
Biology Platform, Sunnybrook Research Institute, Toronto, Canada.
Department of Immunology, University of Toronto, Toronto, Canada.
Cancer Med. 2025 Apr;14(8):e70881. doi: 10.1002/cam4.70881.
It is an unclear how cholesterol-lowering statin drugs affect progression of chronic lymphocytic leukemia (CLL).
Clinical records of 57 CLL patients were examined to determine how initiating statins in the "watch and wait" phase of management affected disease progression.
After 6.4 ± 0.6 months, when average low-density lipoprotein cholesterol levels had been lowered from 3.58 ± 0.11 mM to 2.1 ± 0.06 mM, blood levels of CLL cells and beta-2-microglobulin (β2M) increased significantly, accompanied by significant decreases in platelets. Following statin institution, rates of change of blood lymphocytes and β2M increased from 1.55 ± 0.39 × 10 to 3.4 ± 0.68 × 10 cells/mL/month (n = 43) and 0.035 ± 0.011 to 0.055 ± 0.007 μg/mL/month (n = 40), respectively. Conventional first-line CLL treatment was ultimately required in 37 patients.
These observations suggest that statins as single agent do not slow and may even modestly stimulate progression of CLL.
目前尚不清楚降胆固醇他汀类药物如何影响慢性淋巴细胞白血病（CLL）的进展。
检查了57例CLL患者的临床记录，以确定在“观察等待”管理阶段开始使用他汀类药物如何影响疾病进展。
6.4±0.6个月后，当平均低密度脂蛋白胆固醇水平从3.58±0.11mM降至2.1±0.06mM时，CLL细胞和β2微球蛋白（β2M）的血液水平显著升高，同时血小板显著减少。使用他汀类药物后，血液淋巴细胞和β2M的变化率分别从1.55±0.39×10增至3.4±0.68×10细胞/毫升/月（n = 43）和从0.035±0.011增至0.055±0.007μg/毫升/月（n = 40）。最终37例患者需要进行常规一线CLL治疗。
这些观察结果表明，他汀类药物作为单一药物不会减缓甚至可能适度刺激CLL的进展。
